During the past decade, Sarah Cannon Cancer Center conducted 146 clinical trials. In the 10-year time frame, 146 clinical trials started and 57 clinical trials were completed, i.e. on average, 39% percent of trials that started reached the finish line to date. In the past 5 years, 78 clinical trials started and 38 clinical trials were completed. i.e. 48.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 20 trials, followed by "Eli Lilly and Company" with 14 trials sponsored, "Novartis Pharmaceuticals" with 13 trials sponsored, "Celgene" with 11 trials sponsored and "Seagen Inc." with 11 trials sponsored. Other sponsors include 158 different institutions and companies that sponsored additional 111 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 11 trials as a collaborator, "National Cancer Institute (NCI)" with 9 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Bayer" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Cancer Center" are "Breast Cancer" (20 trials), "Melanoma" (13 trials), "Colorectal Cancer" (10 trials), "Pancreatic Cancer" (10 trials) and "Cancer" (9 trials). Many other conditions were trialed in "Sarah Cannon Cancer Center" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Cancer Center" are "Drug" (197 trials), "Biological" (35 trials), "Other" (11 trials), "Procedure" (7 trials) and "Genetic" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Atezolizumab" (15 trials), "Paclitaxel" (10 trials), "Trastuzumab" (10 trials) and "Carboplatin" (9 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Cancer Center" are 207 trials for "All" genders, 21 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Sarah Cannon Cancer Center". undefined are not yet recruiting, 51 are recruiting, 48 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 97 completed trials in Sarah Cannon Cancer Center, undefined suspended trials, and 27 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Cancer Center, 104 "Phase 1" clinical trials were conducted, 111 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".